CRYOFOCUS-B (06922) announced that following the approval granted by the National Medical Products Administration (NMPA) on January 9, 2024, for other components (namely single-use cryoprobes) of the group's cryoablation adhesion treatment system, one of the group's respiratory intervention products, the registration modification from single-use cryoprobe to cryoprobe has received NMPA approval on August 5, 2025.

With the receipt of these approvals from the NMPA, the group's commercialization pathway for the cryoablation adhesion treatment system will be further enhanced, allowing the cryoprobe to provide comprehensive coverage for relevant indications with both single-use and reusable product characteristics.

The cryoablation adhesion treatment system employs subcritical refrigeration technology and controlled pressure heat transfer technology for rapid cryoablation adhesion. It will be used for the cryogenic removal of foreign objects, mucus, blood clots, and necrotic tissue within airways, as well as for cryobiopsy of bronchial and lung tissue.